Biparametric Prostate MRI: Diagnostic Performance, Estimated Additional Cost of DCE, and Gadolinium Avoidance

Biparametric MRI, which excludes dynamic contrast-enhanced imaging, may reduce the resources required for prostate MRI. This exploratory study assessed biparametric MRI findings against biopsy histopathology in a selected cohort and described differences from the original clinical multiparametric MRI readings. A retrospective convenience sample of 89 prostate MRI examinations with an available biparametric reassessment after removal of dynamic contrast-enhanced sequences was identified. Four patients without a classifiable histopathological diagnosis were excluded, leaving 85 patients for analysis. All had undergone biopsy following a suspicious clinical multiparametric MRI report. Two experienced radiologists each reviewed a portion of the biparametric MRI examinations while blinded to histopathology and the original multiparametric MRI report. Clinically significant prostate cancer, defined as Gleason score ≥3 + 4 (Grade Group ≥ 2), was the primary outcome. PI-RADS > 3 was considered positive. Prostate cancer was detected in 47 of 85 patients (55.3%), including 34 (40.0%) with clinically significant disease. Biparametric MRI classified 33 of 34 clinically significant cancers as PI-RADS > 3, corresponding to a sensitivity of 97.1% (95% CI, 85.1–99.5%). The corresponding sensitivity of the original clinical multiparametric MRI readings was 91.2% (95% CI, 77.0–97.0%; exploratory paired comparison, p = 0.50). Omitting dynamic contrast-enhanced imaging was estimated to reduce examination time, administered gadolinium, and the use of contrast-related materials and staff capacity under local workflow assumptions. In this selected biopsy cohort, biparametric MRI classified 33 of 34 clinically significant cancers as PI-RADS > 3. The comparison with the original multiparametric MRI readings was exploratory and cannot establish equivalence or non-inferiority. Avoiding dynamic contrast-enhanced imaging may reduce contrast administration and resource use, although the economic estimates are specific to the local workflow and environmental release was not measured.

Authors

Institutions

Publication Details

Journal
Journal of Imaging
Published
2026-09-27
DOI
https://doi.org/10.3390/jimaging12100470
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Biparametric Prostate MRI: Diagnostic Performance, Estimated Additional Cost of DCE, and Gadolinium Avoidance

Lorenzo Mellini, Aldo Carnevale, Nicola Pegoraro, Gian Carlo Parenti et al.
Journal of Imaging
Prostate Cancer Diagnosis and Treatment
article

Biparametric Prostate MRI: Diagnostic Performance, Estimated Additional Cost of DCE, and Gadolinium Avoidance

Lorenzo Mellini, Aldo Carnevale, Nicola Pegoraro, Gian Carlo Parenti, Francesco Feletti, Emidio Colleluori, Marcello Pasqualini, Giuseppe Falcone
article en

Abstract

Biparametric MRI, which excludes dynamic contrast-enhanced imaging, may reduce the resources required for prostate MRI. This exploratory study assessed biparametric MRI findings against biopsy histopathology in a selected cohort and described differences from the original clinical multiparametric MRI readings. A retrospective convenience sample of 89 prostate MRI examinations with an available biparametric reassessment after removal of dynamic contrast-enhanced sequences was identified. Four patients without a classifiable histopathological diagnosis were excluded, leaving 85 patients for analysis. All had undergone biopsy following a suspicious clinical multiparametric MRI report. Two experienced radiologists each reviewed a portion of the biparametric MRI examinations while blinded to histopathology and the original multiparametric MRI report. Clinically significant prostate cancer, defined as Gleason score ≥3 + 4 (Grade Group ≥ 2), was the primary outcome. PI-RADS > 3 was considered positive. Prostate cancer was detected in 47 of 85 patients (55.3%), including 34 (40.0%) with clinically significant disease. Biparametric MRI classified 33 of 34 clinically significant cancers as PI-RADS > 3, corresponding to a sensitivity of 97.1% (95% CI, 85.1–99.5%). The corresponding sensitivity of the original clinical multiparametric MRI readings was 91.2% (95% CI, 77.0–97.0%; exploratory paired comparison, p = 0.50). Omitting dynamic contrast-enhanced imaging was estimated to reduce examination time, administered gadolinium, and the use of contrast-related materials and staff capacity under local workflow assumptions. In this selected biopsy cohort, biparametric MRI classified 33 of 34 clinically significant cancers as PI-RADS > 3. The comparison with the original multiparametric MRI readings was exploratory and cannot establish equivalence or non-inferiority. Avoiding dynamic contrast-enhanced imaging may reduce contrast administration and resource use, although the economic estimates are specific to the local workflow and environmental release was not measured.

Journal of ImagingVol. 12(10)
University of Ferrara (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Azienda Unità Sanitaria Locale Della Romagna (IT), Arcispedale Sant'Anna (IT)
Decent work and economic growth
Openalex Percentile: Top 12%
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.